234 related articles for article (PubMed ID: 33762829)
1. Potential Role of Musashi-2 RNA-Binding Protein in Cancer EMT.
Sun J; Sheng W; Ma Y; Dong M
Onco Targets Ther; 2021; 14():1969-1980. PubMed ID: 33762829
[TBL] [Abstract][Full Text] [Related]
2. Interplay between the RNA binding-protein Musashi and developmental signaling pathways.
das Chagas PF; Baroni M; Brassesco MS; Tone LG
J Gene Med; 2020 Jan; 22(1):e3136. PubMed ID: 31692135
[TBL] [Abstract][Full Text] [Related]
3. [Advances in research of Musashi2 in solid tumors].
Yang Y; Zhao M; Ding T; Ni C; Zheng Q; Li X
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Mar; 42(3):448-456. PubMed ID: 35426812
[TBL] [Abstract][Full Text] [Related]
4. Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.
Kudinov AE; Karanicolas J; Golemis EA; Boumber Y
Clin Cancer Res; 2017 May; 23(9):2143-2153. PubMed ID: 28143872
[TBL] [Abstract][Full Text] [Related]
5. MSI2-TGF-β/TGF-β R1/SMAD3 positive feedback regulation in glioblastoma.
Jiang X; Tan J; Wen Y; Liu W; Wu S; Wang L; Wangou S; Liu D; Du C; Zhu B; Xie D; Ren C
Cancer Chemother Pharmacol; 2019 Aug; 84(2):415-425. PubMed ID: 31250154
[TBL] [Abstract][Full Text] [Related]
6. Musashi2 promotes EGF-induced EMT in pancreatic cancer via ZEB1-ERK/MAPK signaling.
Sheng W; Shi X; Lin Y; Tang J; Jia C; Cao R; Sun J; Wang G; Zhou L; Dong M
J Exp Clin Cancer Res; 2020 Jan; 39(1):16. PubMed ID: 31952541
[TBL] [Abstract][Full Text] [Related]
7. Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1.
Lan L; Xing M; Kashipathy M; Douglas J; Gao P; Battaile K; Hanzlik R; Lovell S; Xu L
Proteins; 2020 Apr; 88(4):573-583. PubMed ID: 31603583
[TBL] [Abstract][Full Text] [Related]
8. Musashi-2 (MSI2) supports TGF-β signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis.
Kudinov AE; Deneka A; Nikonova AS; Beck TN; Ahn YH; Liu X; Martinez CF; Schultz FA; Reynolds S; Yang DH; Cai KQ; Yaghmour KM; Baker KA; Egleston BL; Nicolas E; Chikwem A; Andrianov G; Singh S; Borghaei H; Serebriiskii IG; Gibbons DL; Kurie JM; Golemis EA; Boumber Y
Proc Natl Acad Sci U S A; 2016 Jun; 113(25):6955-60. PubMed ID: 27274057
[TBL] [Abstract][Full Text] [Related]
9. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome-wide analysis uncovers the targets of the RNA-binding protein MSI2 and effects of MSI2's RNA-binding activity on IL-6 signaling.
Duggimpudi S; Kloetgen A; Maney SK; Münch PC; Hezaveh K; Shaykhalishahi H; Hoyer W; McHardy AC; Lang PA; Borkhardt A; Hoell JI
J Biol Chem; 2018 Oct; 293(40):15359-15369. PubMed ID: 30126842
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of ovarian cancer cells during epithelial-mesenchymal transition (EMT) induced by epidermal growth factor (EGF) reveals mechanisms of cell cycle control.
Grassi ML; Palma CS; Thomé CH; Lanfredi GP; Poersch A; Faça VM
J Proteomics; 2017 Jan; 151():2-11. PubMed ID: 27394697
[TBL] [Abstract][Full Text] [Related]
12. RNA-binding MSI proteins and their related cancers: A medicinal chemistry perspective.
Liu C; Chen H; Cao S; Guo J; Liu Z; Long S
Bioorg Chem; 2024 Feb; 143():107044. PubMed ID: 38134522
[TBL] [Abstract][Full Text] [Related]
13. Developmental expression of Musashi-1 and Musashi-2 RNA-binding proteins during spermatogenesis: analysis of the deleterious effects of dysregulated expression.
Sutherland JM; Fraser BA; Sobinoff AP; Pye VJ; Davidson TL; Siddall NA; Koopman P; Hime GR; McLaughlin EA
Biol Reprod; 2014 May; 90(5):92. PubMed ID: 24671879
[TBL] [Abstract][Full Text] [Related]
14. Msi2 plays a carcinogenic role in esophageal squamous cell carcinoma via regulation of the Wnt/β-catenin and Hedgehog signaling pathways.
Li Z; Jin H; Mao G; Wu L; Guo Q
Exp Cell Res; 2017 Dec; 361(1):170-177. PubMed ID: 29054489
[TBL] [Abstract][Full Text] [Related]
15. The metastasis suppressor CD82/KAI1 represses the TGF-β
Lee MS; Lee J; Kim YM; Lee H
Prostate; 2019 Sep; 79(12):1400-1411. PubMed ID: 31212375
[TBL] [Abstract][Full Text] [Related]
16. Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process.
Lee HM; Hwang KA; Choi KC
Mol Cell Endocrinol; 2017 Dec; 457():103-113. PubMed ID: 28042023
[TBL] [Abstract][Full Text] [Related]
17. Blockade of Jagged/Notch pathway abrogates transforming growth factor β2-induced epithelial-mesenchymal transition in human retinal pigment epithelium cells.
Chen X; Xiao W; Liu X; Zeng M; Luo L; Wu M; Ye S; Liu Y
Curr Mol Med; 2014 May; 14(4):523-34. PubMed ID: 24694299
[TBL] [Abstract][Full Text] [Related]
18. EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells.
Kim J; Kong J; Chang H; Kim H; Kim A
Oncotarget; 2016 Dec; 7(51):85021-85032. PubMed ID: 27829223
[TBL] [Abstract][Full Text] [Related]
19. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
20. Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway.
Wang MH; Qin SY; Zhang SG; Li GX; Yu ZH; Wang K; Wang B; Teng MJ; Peng ZH
Am J Cancer Res; 2015; 5(3):1089-100. PubMed ID: 26045988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
